Article | Published:

Clinical Study

Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors

British Journal of Cancervolume 118pages13131321 (2018) | Download Citation

Abstract

Background

Testicular cancer survivors (TCS) are at increased risk of cancer-related fatigue (CRF), psychosocial impairment, and poor mental health-related quality of life (HRQoL). Here, we examine the effects of high-intensity interval training (HIIT) on patient-reported outcomes (PROs) in TCS. Secondarily, we explore cardiorespiratory fitness as a mediator of intervention effects and select baseline characteristics as moderators of intervention effects.

Methods

TCS (n = 63) were randomly assigned to 12 weeks of supervised HIIT or usual care (UC). PROs included CRF, depression, anxiety, stress, self-esteem, sleep quality, and HRQoL assessed at baseline, post-intervention, and 3-month follow-up.

Results

TCS (median 7 years postdiagnosis) completed 99% of training sessions and achieved 98% of target training intensity. ANCOVA revealed that, compared to UC, HIIT significantly improved post-intervention CRF (p = 0.003), self-esteem (p = 0.029), and multiple HRQoL domains (ps ≤ 0.05). Effects on CRF (p = 0.031) and vitality (p = 0.015) persisted at 3-month follow-up. Cardiorespiratory fitness changes mediated CRF and HRQoL improvements. CRF effects were larger for TCS with an inactive lifestyle, lower fitness, higher testosterone, and clinical fatigue at baseline.

Conclusions

HIIT significantly improves CRF and HRQoL in TCS. Mediation by cardiorespiratory fitness and moderation by clinical characteristics suggests opportunities for targeted exercise interventions to optimise PROs in TCS.

  • Subscribe to British Journal of Cancer for full access:

    $659

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

Additional information

Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

References

  1. 1.

    Curado, M et al. Cancer Incidence In Five Continents. (IARC Press, Lyon, 2007). .

  2. 2.

    Miller, K. D. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66, 271–289 (2016).

  3. 3.

    Feldman, D. R., Bosl, G. J., Sheinfeld, J. & Motzer, R. J. Medical treatment of advanced testicular cancer. JAMA 299, 672–684 (2008).

  4. 4.

    Haugnes, H. S. et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J. Clin. Oncol. 30, 3752–3763 (2012).

  5. 5.

    Christensen, J. F., Bandak, M., Campbell, A., Jones, L. W. & Hojman, P. Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship. Acta Oncol. 54, 592–599 (2015).

  6. 6.

    Sprauten, M. et al. Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. Ann. Oncol. 26, 2133–2140 (2015).

  7. 7.

    Dahl, A. A. et al. Study of anxiety disorder and depression in long-term survivors of testicular cancer. J. Clin. Oncol. 23, 2389–2395 (2005).

  8. 8.

    Smith, A. B. et al. The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. J. Cancer Surviv 10, 223–233 (2016).

  9. 9.

    Mock, V. et al. NCCN practice guidelines for cancer-related fatigue. Oncology 14, 151–161 (2000).

  10. 10.

    Orre, I. J. et al. Chronic cancer-related fatigue in long-term survivors of testicular cancer. J. Psychosom. Res 64, 363–371 (2008).

  11. 11.

    Oechsle, K. et al. Symptom burden in long-term germ cell tumour survivors. Support Care Cancer 24, 2243–2250 (2016).

  12. 12.

    Mustian, K. M. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 3, 961–968 (2017).

  13. 13.

    Brown, J. C. et al. The efficacy of exercise in reducing depressive symptoms among cancer survivors: a meta-analysis. PloS ONE 7, e30955 (2012).

  14. 14.

    Mishra, S. I., Scherer, R. W., Snyder, C., Geigle, P. & Gotay, C. Are exercise programs effective for improving health-related quality of life among cancer survivors? A systematic review and meta-analysis. Oncol. Nurs. Forum 41, E326–E342 (2014).

  15. 15.

    Thorsen, L. et al. The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Support Care Cancer 13, 637–646 (2005).

  16. 16.

    Fung, C. et al. Multi-institutional assessment of adverse health outcomes among North American testicular cancer survivors after modern cisplatin-based chemotherapy. J. Clin. Oncol. 35, 1211–1222 (2017).

  17. 17.

    Adams, S. C. et al. Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: a phase II randomised controlled trial. Cancer 123, 4057–4065 (2017).

  18. 18.

    Courneya, K. S. et al. Randomised controlled trial of exercise training in postmenopausal breast cancer survivors: Cardiopulmonary and quality of life outcomes. J. Clin. Oncol. 21, 1660–1668 (2003).

  19. 19.

    Buffart, L. M. et al. Fatigue mediates the relationship between physical fitness and quality of life in cancer survivors. J. Sci. Med Sport 16, 99–104 (2013).

  20. 20.

    Courneya, K. S. et al. Randomised controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J. Clin. Oncol. 27, 4605–4612 (2009).

  21. 21.

    Rognmo, O., Hetland, E., Helgerud, J., Hoff, J. & Slordahl, S. A. High intensity aerobic interval exercise is superior to moderate intensity exercise for increasing aerobic capacity in patients with coronary artery disease. Eur. J. Cardiovasc Prev. Rehabil. 11, 216–222 (2004).

  22. 22.

    Mezzani, A. et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur. J. Prev. Cardiol. 20, 442–467 (2013).

  23. 23.

    Godin, G. & Shephard, R. J. A simple method to assess exercise behavior in the community. Can. J. Appl. Sport Sci. 10, 141–146 (1985).

  24. 24.

    Schmitz, K. H. et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci. Sports Exerc 42, 1409–1426 (2010).

  25. 25.

    Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C. & Kaplan, E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J. Pain. Symptom Manag. 13, 63–74 (1997).

  26. 26.

    Kohout, F. J., Berkman, L. F., Evans, D. A. & Cornoni-Huntley, J. Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index. J. Aging Health 5, 179–193 (1993).

  27. 27.

    Spielberger, C. D, Gorsuch, R. L, Lushene, R, Vagg, P. R. & Jacobs, G. A. Manual For The State-trait Anxiety Inventory. (Consulting Psychologists Press, Palo Alto, 1983).

  28. 28.

    Cohen, S., Kamarck, T. & Mermelstein, R. A global measure of perceived stress. J. Health Soc. Behav. 24, 385–396 (1983).

  29. 29.

    Rosenberg, M Society And The Adolescent Self-image. Vol.11 (Princeton University Press, Princeton, 1965).

  30. 30.

    Beck, S. L., Schwartz, A. L., Towsley, G., Dudley, W. & Barsevick, A. Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. J. Pain. Symptom Manag. 27, 140–148 (2004).

  31. 31.

    Ware, J. E et al. User’s Manual for the SF-36v2 Health Survey. 2nd edn. (Quality Metric Incorporated, Lincoln, 2011).

  32. 32.

    MacKinnon, D. P Introduction To Statistical Mediation Analysis. (Lawrence Erlbaum Associates, New York, 2008).

  33. 33.

    Hayes, A. F Introduction To Mediation, Moderation, And Conditional Process Analysis: A Regression-based Approach. 2nd edn. (Guilford Press, New York, 2013).

  34. 34.

    Preacher, K. J. & Hayes, A. F. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav. Res Methods Instrum. Comput. 36, 717–731 (2004).

  35. 35.

    Borm, G. F., Fransen, J. & Lemmens, W. A. A simple sample size formula for analysis of covariance in randomised clinical trials. J. Clin. Epidemiol. 60, 1234–1238 (2007).

  36. 36.

    Cella, D., Eton, D. T., Lai, J. S., Peterman, A. H. & Merkel, D. E. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J. Pain. Symptom Manag. 24, 547–561 (2002).

  37. 37.

    Daussin, F. N. et al. Effect of interval versus continuous training on cardiorespiratory and mitochondrial functions: relationship to aerobic performance improvements in sedentary subjects. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295, R264–R272 (2008).

  38. 38.

    Wisloff, U. et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: A randomised study. Circulation 115, 3086–3094 (2007).

  39. 39.

    Cormie, P. et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 115, 256–266 (2015).

  40. 40.

    Burney, B. O. & Garcia, J. M. Hypogonadism in male cancer patients. J. Cachex-. Sarcopenia Muscle 3, 149–155 (2012).

  41. 41.

    Bhasin, S. Testosterone supplementation for aging-associated sarcopenia. J. Gerontol. A Biol. Sci. Med Sci. 58, 1002–1008 (2003).

  42. 42.

    Caminiti, G. et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomised study. J. Am. Coll. Cardiol. 54, 919–927 (2009).

  43. 43.

    Courneya, K. S. et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomised controlled trial. J. Clin. Oncol. 25, 4396–4404 (2007a).

  44. 44.

    Rossen, P., Pedersen, A. F., Zachariae, R. & von der Maase, H. Sexuality and body image in long-term survivors of testicular cancer. Eur. J. Cancer 48, 571–578 (2012).

  45. 45.

    van Basten, J. P. et al. Fantasies and facts of the testes. Br. J. Urol. 78, 756–762 (1996).

  46. 46.

    Courneya, K. S. et al. Six-month follow-up of patient-rated outcomes in a randomised controlled trial of exercise training during breast cancer chemotherapy. Cancer Epidemiol. Biomark. Prev. 16, 2572–2578 (2007b).

  47. 47.

    Rogers, L. Q. et al. Physical activity and health outcomes three months after completing a physical activity behavior change intervention: persistent and delayed effects. Cancer Epidemiol. Biomark. Prev. 18, 1410–1418 (2009).

Download references

Acknowledgements

We thank all HIITTS trial participants for their dedication and time, without which this study would not have been possible.

Author contributions

Conception and design: All authors. Acquisition, analysis, or interpretation of the data: All authors. Drafting the article: S.C.A. Reviewing the article: All authors. Final approval of article: All authors.

Author information

Author notes

    • Scott C Adams

    Present address: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10017, USA

Affiliations

  1. Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, AB, T6G 2H9, Canada

    • Scott C Adams
    • , Darren S DeLorey
    • , Margie H Davenport
    •  & Kerry S Courneya
  2. Department of Surgery, University of Alberta, Edmonton, AB, T6G 2B7, Canada

    • Adrian S Fairey
  3. Alberta Urology Institute Research Centre, Edmonton, AB, T6G 1Z1, Canada

    • Adrian S Fairey
  4. Department of Oncology, University of Alberta, Edmonton, AB, T6G 2R7, Canada

    • Scott North
  5. Cross Cancer Institute, Edmonton, AB, T6G 1Z2, Canada

    • Scott North

Authors

  1. Search for Scott C Adams in:

  2. Search for Darren S DeLorey in:

  3. Search for Margie H Davenport in:

  4. Search for Adrian S Fairey in:

  5. Search for Scott North in:

  6. Search for Kerry S Courneya in:

Competing interests

The authors declare no competing interests.

Ethical approval:

All procedures complied with the ethical standards of the local (University of Alberta), regional (Health Research Ethics Board of Alberta–Cancer Committee), and national (Canadian Institutes of Health Research) committees on human experimentation and the Helsinki Declaration.

Informed consent

Informed consent was obtained for all study participants prior to study inclusion.

Availability of data & material

Study data is available upon request.

Corresponding author

Correspondence to Kerry S Courneya.

Electronic supplementary material

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41416-018-0044-7

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.